GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) are contraindicated during breastfeeding per UK Summary of Product Characteristics No weight loss injection currently has regulatory approval for use whilst breastfeeding in the UK Transfer into breast milk and effects on nursing infants remain unknown due to absence of human studies Appetite suppression from these medications may compromise maternal nutrition needed for adequate milk production Safe alternatives include gradual dietary modification, regular physical activity, and NHS weight management programmes Women should defer weight loss medications until breastfeeding is completed and seek GP advice for postpartum weight concerns Table of Contents Weight Loss Injections and Breastfeeding: Key Safety Considerations Types of Weight Loss Injections and Their Use During Lactation Potential Risks to Breastfed Infants Alternative Approaches to Postpartum Weight Management When to Seek Medical Advice About Weight Loss While Breastfeeding Scientific References Frequently Asked Questions Weight Loss Injections and Breastfeeding: Key Safety Considerations Weight loss injections, particularly GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda), have become increasingly popular for weight management

Amgen's MariTide, which combines GLP-1 agonism with GIP antagonism, was specifically designed based on genetic evidence suggesting this combination could reduce nausea while maintaining weight loss efficacy [44]
[9] [14] This dual action helps maintain blood glucose within the normal range, particularly after meals when glucose levels naturally rise
While the risk of hypoglycemia is low with GLP-1 receptor agonists alone, this risk increases when combined with insulin or sulfonylureas
-25% HAYA LABS Basic Adult Multivitamin / 100 Tabs 8.44 / 16.51
It slows digestion, reduces cravings, and helps you feel full sooner and for longer periods